PARP (Poly ADP-Ribose Polymerase) inhibitor biomarkers are used for the stratification of patients with certain cancers like breast and ovarian cancer into those likely to respond to PARP inhibitor treatment and those unlikely to respond. They play an important role as companion diagnostics alongside PARP inhibitors drugs to identify patients with homologous recombination deficiency (HRD)...
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian